Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03803475 · ClinicalTrials.gov registry record · Phase 3
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
A Phase 3 study, sponsored by Thomas Hope.
- Completed
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
NCT03803475: Completed Phase 3 study, sponsored by Thomas Hope.
NCT03803475 is a Phase 3 study that has completed, run by Thomas Hope. The registered enrollment target is 485 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03803475, a Phase 3 study, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
Primary Outcome
Detection rate is defined as the proportion of all patients who have prostate cancer and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging.
Interventions
- DRUG Ga-68 labeled PSMA-11
- DEVICE Positron emission tomography-computed tomography (PET/CT)
- DEVICE Positron emission tomography-magnetic resonance imaging (PET/MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 3 |
What the finished NCT03803475 record still lists
NCT03803475 is an interventional study that assigns participants to a tested intervention. The registered 485 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 3 interventions - of which Ga-68 labeled PSMA-11 is the first listed.
NCT03803475 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03803475 about?
NCT03803475 is a clinical study titled "Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients". The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
What is the current status of trial NCT03803475?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2018-10-11. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT03803475?
The interventions under investigation include: Ga-68 labeled PSMA-11 (DRUG), Positron emission tomography-computed tomography (PET/CT) (DEVICE), Positron emission tomography-magnetic resonance imaging (PET/MRI) (DEVICE).
Who is sponsoring clinical trial NCT03803475?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03803475's enrollment target sits among peer trials
485 790th of 2000 higher than 1,210 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI